Pfizer, the world's biggest pharma company, is increasing its stake in emerging markets, with its announcement on 20 October 2010 that it has entered into an agreement to acquire a 40% stake in Brazilian generics’ manufacturer Laboratorio Teuto Brasileiro (Teuto) for US$240 million.
Pfizer buys 40% stake in Brazilian generics’ manufacturer Teuto
Home/Pharma News
|
Posted 21/01/2011
0
Post your comment

Along with the 40% stake in Teuto, the companies will also enter into a series of commercial agreements. The partnership is expected to enhance Pfizer’s position in Brazil, a key emerging market, by providing access to Teuto’s broad portfolio of approximately 250 products. Pfizer also gains access to significant distribution networks in rural and suburban areas in Brazil and the opportunity to register and commercialise Teuto’s products in markets outside Brazil.
Teuto in return will gain access to selected Pfizer products for distribution across its extensive distribution network and will have the right to commercialise them under Teuto’s own brand in Brazil.
Under the terms of the agreement, Teuto is also eligible to receive a performance-based milestone payment and Pfizer also has an option to acquire the remaining 60% of Teuto’s shares beginning in 2014.
Teuto products include both branded and unbranded generic medicines, covering a broad range of therapeutic areas, such as pain and inflammation, cardiovascular, anti-infectives, central nervous system and respiratory, among others.
In 2008, the global generics marketplace represented US$750 billion and is anticipated to grow up to US$920 billion by 2013, with the bulk of this growth generated in emerging markets. Today, branded and unbranded generics account for approximately 60% of the value of the Brazilian retail pharmaceutical market.
President of Pfizer's Emerging Markets Business Unit, Mr Jean-Michel Halfon, said “this agreement demonstrates Pfizer’s commitment to pursue focused investments in key emerging markets to accelerate our growth and increase patient access to high-quality medicines”.
The Teuto deal follows the announcement just days ago of a deal by Pfizer with Indian biotech company Biocon concerning biosimilar insulin products.
Related article
Pfizer and India-based Biocon make biosimilar insulin deal
Source: Pfizer, Biocon.
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment